SCHEMBL7669757

SCHEMBL7669757

Brc1cccc(Oc2cccc(Br)c2Cc2ccccc2)c1Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.44
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MAPK1 P28482 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 1/20 0.37
LTA4H P09960 1/20 0.36
ALDH1A1 P00352 2/20 0.36
LOXL2 Q9Y4K0 1/20 0.36
TRPA1 O75762 1/20 0.36
TSHR P16473 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
STAT3 P40763 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29029452 0.81 ALDH1A1 (0.40) CALM1MAPTTDP1L3MBTL1MAPK1
SCHEMBL29029437 0.80 TSHR (0.39) CALM1TDP1L3MBTL1MEN1KMT2A
SCHEMBL7033288 0.79 HPGD (0.49) CALM1LMNAL3MBTL1SMN1; SMN2HPGD
SCHEMBL9816698 0.79 DPP4 (0.50) CALM1LMNAMAPTMEN1KMT2A
SCHEMBL28044203 0.78 CALM1 (0.42) CALM1LMNAMEN1KMT2AKDM4E
SCHEMBL7632931 0.78 BCL2 (0.45) CALM1LMNAMEN1KMT2AHPGD
SCHEMBL27286175 0.78 ALDH1A1 (0.48) CALM1MAPTTDP1L3MBTL1MAPK1
SCHEMBL393291 0.78 CALM1 (0.42) CALM1LMNAMAPTTDP1L3MBTL1
SCHEMBL9235387 0.78 L3MBTL1 (0.46) CALM1LMNAMAPTTDP1L3MBTL1
Ethylene SCHEMBL28237007 0.76 HPGD (0.46) CALM1LMNAL3MBTL1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020035092-A1 Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid CELLTECH THERAPEUTICS LIMITED 2002-03-21 US disclosed
US-6319922-B1 ALPHA-PYRIMIDYL-SUBSTITUTED; USEFUL FOR TREATING DISEASES INCLUDING INFLAMMATORY DISEASES, AND DISEASES INVOLVING ANGIOGENESIS, BONE RESORPTION OR CELLULAR OR MATRIX OVER-EXPANSION. CELLTECH THERAPEUTICS LIMITED (GB) 2001-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035092-A1 Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid ITGA1, ITGB1, VCAM1 CALM1 1045/4885LMNA 2856/4885MAPT 4599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.